WuXi Biologics (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in China, has announced the successful completion of the inaugural manufacturing batch at its state-of-the-art drug substance facility, MFG7, located in Ireland. This milestone marks a significant step towards facilitating large-scale commercial manufacturing projects at the site.
MFG7, which began operations in March 2022, received its first Good Manufacturing Practice (GMP) certificate from the Irish Health Products Regulatory Authority (HPRA) in December 2022. The recent manufacturing run demonstrated the facility’s capability to scale up production to 16,000 liters by integrating four 4,000-liter single-use bioreactors, reinforcing WuXi Biologics’ commitment to delivering high-quality biopharmaceutical products at a commercial scale.
This achievement underscores WuXi Biologics’ global expansion strategy and enhances its position as a premier CRDMO partner, capable of supporting the biopharmaceutical industry’s growing needs for advanced manufacturing solutions.- Flcube.com
